Indian pharma patents insulin eye drops

ENTOD Pharmaceuticals has secured a patent for topical insulin eye drops, a novel approach to treating eye disease. The Mumbai-based company describes this as a major step in advancing indigenous pharmaceutical research.

“This patent is not just a scientific achievement, but also a testament to India's growing ability to create original pharmaceutical innovation.”

Still in early research phase

The insulin eye drops are currently at the pre-clinical stage of development. Further research will be needed to establish safety, efficacy, and potential clinical applications.

India shifts beyond generic drugs

India's pharmaceutical industry is increasingly moving beyond manufacturing generics toward original research and novel drug development. This patent reflects the country's growing intellectual property creation capabilities.

Insulin's unexpected eye care potential

Insulin is well-known for diabetes treatment, but scientists are exploring its biological properties for eye disease. Delivering insulin through eye drops represents an innovative new route of administration for this established molecule.

“Insulin is familiar to most people as an essential treatment for diabetes, but its biological role has made it a subject of scientific interest far beyond blood sugar management.”

Expert sees promise in novel approach

Dr. B Vijaya Lakshmi from Sarojini Devi Eye Hospital says exploring insulin through eye drops is an innovative direction for ophthalmic research. She emphasizes that rigorous clinical studies are needed to establish safety and therapeutic value.

“While its safety and therapeutic value will need to be established through rigorous research and clinical studies, it is innovations such as these that encourage us to look beyond conventional approaches.”